MaxCyte stock fell 1.83 percent as Q2 revenue dropped 15 percent

Published on 10/04/2026 at 09:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MaxCyte stock reflects Q2 revenue of USD 7.3 million, down 15 percent year over year. Management kept 2026 guidance at USD 30 million to USD 32 million after the August 12 report.

MXCT, US57777K1060, Illustration mit AI erstellt.

MaxCyte stock (ISIN US57777K1060) was last at USD 1.07 on Nasdaq on October 2, 2026, at 4:00 p.m. ET, down 1.83 percent from the prior close. On September 23, MaxCyte appointed Sidharth Kapileshwar as chief corporate development officer, according to Markets Insider.

Q2 revenue fell 15 percent

In the Q2 earnings call dated August 12, 2026, MaxCyte reported USD 7.3 million of total revenue, down 15 percent from USD 8.5 million in Q2 2025, according to The Globe and Mail. Core revenue fell 21 percent year over year to USD 6.5 million, while SPL program-related revenue rose to USD 0.8 million from USD 0.3 million.

The earnings mix shows the central tension in the stock. MaxCyte's GAAP gross margin was 77 percent in Q2 2026, down from 82 percent a year earlier, while the net loss improved to USD 8.9 million from USD 12.4 million.

Guidance stayed at USD 30 million

MaxCyte reiterated total 2026 revenue guidance of USD 30 million to USD 32 million, including USD 25 million to USD 27 million of core revenue and USD 5 million from SPL milestones and royalties, according to The Globe and Mail. Management expects low single-digit year-over-year growth in the second half, with instrument placements and processing assembly demand serving as key drivers.

MarketBeat reported on September 6, 2026, that analyst consensus stood at Hold with a USD 5.00 target price. That target is USD 3.93 above the October 2 price, or 78.6 percent above it, making the forecast gap substantial while the company works through revenue volatility.

The yearly range remains wide

MaxCyte stock traded between USD 0.64 and USD 1.87 over the 52-week period as of October 2, 2026. Its market capitalization was USD 114.6 million on the same date, and session volume reached 228,089 shares.

The October 2 price snapshot

For investors, the key checkpoint is whether the reiterated USD 30 million to USD 32 million revenue outlook can translate into the second-half growth management described on August 12, 2026. The reference price was USD 1.07 on Nasdaq on October 2, 2026, at 4:00 p.m. ET, with a daily change of minus 1.83 percent.